CLAIMS

1. A double-stranded microRNA mimic for the treatment of malignant pleural mesothelioma (MPM), wherein the microRNA mimic comprises:

(a) a mature sequence corresponding to a miR-15/107 family member; and

(b) a passenger strand,

wherein the mature sequence contains AGCAGC at positions 2-7 or 1-6 at the 5' end.

2. The double-stranded RNA microRNA mimic of claim 1, wherein the mature sequence comprises a sequence selected from the group consisting of SEQ ID NOS: 11-14.

3. The double-stranded microRNA mimic of claim 1, wherein the passenger strand comprises a sequence selected from the group consisting of SEQ ID NOS: 15-18.

4. The double-stranded microRNA mimic of claim 1, wherein the passenger strand is inactivated by chemical modification.

5. A method for treating MPM in a subject having MPM, comprising administering to a subject an effective amount of a double-stranded microRNA mimic according to claim 1.

6. The method according to claim 5, wherein the step of administering further comprises the use of a minicell to deliver the microRNA mimic.

7. The method according to claim 5, wherein administration of the microRNA mimic to the subject comprises simultaneous or serial co-administration of an adjunct anti-cancer therapy.

8. A method for increasing sensitivity of a MPM cancer cell to an anti-cancer therapy, comprising administering to the MPM cancer cell the microRNA mimic according to claim 1.

CLAIMS

1. A double-stranded microRNA mimic, comprising:

(a) a mature sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 11 to 14; and

(b) a passenger strand.

2. A double-stranded microRNA mimic according to Claim 1, in which the passenger strand comprises a sequence selected from the group consisting of SEQ ID NOs: 15 to 18.

3. A double-stranded microRNA mimic according to Claim 1 or 2, in which the passenger strand is inactivated by chemical modification.

4. Use of a double-stranded microRNA mimic according to Claim 1, 2 or 3 in the manufacture of a medicament for treating MPM.

5. Use according to Claim 4, in which the mimic is provided for administration with a minicell.

6. Use according to Claim 4 or 5, in which the mimic is provided for co-administration simultaneously or serially with an adjunct anticancer therapy.

7. Use of a microRNA mimic according to Claim 1, 2 or 3 in the manufacture of a medicament for increasing sensitivity of a MPM cancer cell to an anti-cancer therapy.

8. A microRNA mimic according to any of Claims 1, 2 or 3 for use in medicine.